Tucidinostat Plus R-CHOP vs R-CHOP in MYC/BCL2 Double-Expressor Diffuse Large B-Cell Lymphoma
JAMA · 19.05.2026 · 335 (19) · 1684
DOI: 10.1001/jama.2026.4199 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JAMA, erschienen am 19.05.2026. Verfasst von Peng-Peng Xu und 44 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics; National Research Center for Translational Medicine at Shanghai, Ruijin H…. Hauptthemen laut MEDLINE: Aminopyridines, Antineoplastic Combined Chemotherapy Protocols, Histone Deacetylase Inhibitors, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Epigenetic dysregulation is associated with the pathogenesis and progression of diffuse large B-cell lymphoma (DLBCL). MYC/BCL2 double-expressor lymphoma (DEL), a distinct population of DLBCL defined by MYC and BCL2 coexpression, refers to poor prognosis after standard rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) immunochemotherapy. Tucidinostat (or chidamide), an oral, selective histone deacetylase inhibitor, has shown promising activity in DEL.
Objective
To evaluate efficacy and safety of tucidinostat plus R-CHOP vs R-CHOP alone as first-line treatment for patients with DEL. Design, Setting, and Participants This randomized, double-blind, placebo-controlled phase 3 trial enrolled patients from May 21, 2020, through July 25, 2022, with follow-up to June 26, 2025. The trial was conducted at 40 study centers in China; a total of 423 eligible patients were enrolled.
Interventions
Patients were randomly assigned in a 1:1 ratio to receive oral tucidinostat (20 mg on days 1, 4, 8, and 11 of each 21-day cycle) or matching placebo, plus 6 cycles of R-CHOP. Patients with a complete response after combination therapy received either tucidinostat or placebo maintenance up to 24 weeks. Main Outcomes and Measures The primary end point was event-free survival. Secondary end points included complete response rate, progression-free survival, disease-free survival, overall survival, and tolerability.
Results
Among 423 patients randomized (median age, 63 years; 47.5% male), the median follow-up duration from randomization was 41.3 months. The tucidinostat group demonstrated a 28% lower risk of disease progression, relapse after complete response, death, or initiation of new therapy for residual disease compared with the placebo group (stratified hazard ratio, 0.72 [95% CI, 0.54-0.96]; P = .02), with a 2-year event-free survival rate of 60.3% vs 50.5%, respectively. The complete response rate was 73.0% vs 61.8% (difference, 11.1% [95% CI, 2.3%-20.0%]), respectively. Increased toxicity associated with treatment was observed in the tucidinostat group but generally manageable with supportive care. Conclusions and Relevance Tucidinostat plus R-CHOP significantly improved event-free survival, with manageable toxicity in patients newly diagnosed with DEL. This trial is the first to demonstrate the benefit of an epigenetic modulator in DLBCL, offering a new first-line therapeutic approach dually targeting MYC and BCL2 oncoprotein for this high-risk population. Trial Registration ClinicalTrials.gov Identifier: NCT04231448
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics; National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine…
- Peking University Cancer Hospital & Institute (Beijing Cancer Hospital), Beijing, China.
- Fujian Medical University Union Hospital, Fuzhou, China.
- Sun Yat-sen University Cancer Center, Guangzhou, China.
- Hunan Cancer Hospital, Changsha, China.
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Zitieren
APA
Xu, P. P., Song, Y. Q., Shen, J. Z., Cai, Q. Q., Zhou, H., Zhang, L. L., Xiang, Y., Sun, X. H., Yang, W., Yao, Z. H., Jing, H. M., Wen, S. J., Jin, J., Xue, H. W., Cen, H., Ding, K. Y., Jin, Z. M., Liu, L. H., Xing, X. J., …, & Zhao, W. L. (2026). Tucidinostat Plus R-CHOP vs R-CHOP in MYC/BCL2 Double-Expressor Diffuse Large B-Cell Lymphoma. JAMA, 335(19), 1684. https://doi.org/10.1001/jama.2026.4199
Vancouver
Xu PP, Song YQ, Shen JZ, Cai QQ, Zhou H, Zhang LL, et al. Tucidinostat Plus R-CHOP vs R-CHOP in MYC/BCL2 Double-Expressor Diffuse Large B-Cell Lymphoma. JAMA. 2026;335(19):1684. doi:10.1001/jama.2026.4199
BibTeX
@article{Xu2026,
author = {Xu, Peng-Peng and Song, Yu-Qin and Shen, Jian-Zhen and Cai, Qing-Qing and Zhou, Hui and Zhang, Li-Ling and Xiang, Ying and Sun, Xiu-Hua and Yang, Wei and Yao, Zhi-Hua and Jing, Hong-Mei and Wen, Shu-Juan and Jin, Jie and Xue, Hong-Wei and Cen, Hong and Ding, Kai-Yang and Jin, Zheng-Ming and Liu, Li-Hong and Xing, Xiao-Jing and Li, Lan-Fang and Hou, Ming and Liu, Lin and Zhang, Ming-Zhi and Li, Wen-Yu and Bai, Ou and Feng, Ru and Zhu, Zun-Min and Wu, Hui-Jing and Su, Li-Ping and Gao, Li and Li, Fei and Huang, Wen-Rong and Liu, Peng and Yan, Xiao-Jing and Zhao, Ying and Su, Hang and Zhao, Xie-Lan and Fu, Rong and Liu, Hong and Shi, Wen-Yu and Li, Hui-Zhi and Chen, Bo and Ning, Zhi-Qiang and Zhu, Jun and Zhao, Wei-Li},
title = {Tucidinostat Plus R-CHOP vs R-CHOP in MYC/BCL2 Double-Expressor Diffuse Large B-Cell Lymphoma},
journal = {JAMA},
year = {2026},
volume = {335},
number = {19},
pages = {1684},
doi = {10.1001/jama.2026.4199}
}
EUVIMED